Sahajanand Medical Technologies (SMT), a global leader in cardiovascular device innovation, is pleased to announce the appointment of two new members to its Board of Directors: Harvinder Pal Singh, who will serve as Independent Director, and Priyanka Dhirajlal Cohen, who joins as Non-Executive Director.

Harvinder Pal Singh Brings World-Class MedTech Leadership

Harvinder Pal Singh joins SMT with a distinguished career in the medical technology sector. He is the current Executive Vice President and President, International, at Integra Life Sciences Corporation, where he has led global commercial operations. Prior to this, he held senior commercial leadership roles at Abbott Laboratories, contributing significantly to market expansion and innovation initiatives. SMT believes Singh’s proven track record in penetrating international markets and driving commercial excellence will be pivotal to its worldwide growth strategy

Priyanka Dhirajlal Cohen Enhances Governance with Legal Expertise

Priyanka Dhirajlal Cohen, a veteran trial attorney and a key promoter of SMT, brings substantial expertise in corporate law, regulatory governance, and public policy. Her career includes significant roles at the U.S. Department of Justice and the District of Columbia Court of Appeals . SMT anticipates that her legal acumen and public service background will greatly strengthen board oversight and strategic decision-making

Chairman’s Statement

Jose Calle Gordo, Chairman of SMT, stated:

We are thrilled to welcome Harvinder Singh and Priyanka Cohen to the SMT Board. Singh’s global MedTech expertise and proven record in building high‑performance businesses aligns with SMT’s next phase of international expansion. Cohen brings a unique blend of legal expertise and policy insight that will be instrumental in steering SMT’s governance and long‑term strategy.”

Accelerating SMT’s Global Vision

The new board appointments are a strategic step to bolster SMT’s leadership framework as the company scales internationally. These additions come at a pivotal time, as SMT continues to enhance its presence across Europe, Latin America, Asia-Pacific, and North America—supported by its robust manufacturing and R\&D infrastructure. SMT operates three advanced R\&D centers (India, Ireland, Thailand) and multiple production facilities, driving innovation in cardiovascular and peripheral therapies

Strategic Outlook

With Singh’s commercial leadership and Cohen’s legal and regulatory insight, SMT is well positioned to:

Expand its global market footprint, leveraging Singh’s experience in scaling MedTech businesses internationally.
Strengthen corporate governance and compliance frameworks, driven by Cohen’s policy and legal expertise.
Support R\&D-driven innovation, as SMT accelerates its development pipeline through CE/US FDA approvals and market access.